Synarel (nafarelin) / Pfizer - LARVOL DELTA

Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Shaare Zedek Medical Center

New P1 trial

INFORM: Intranasal Nafarelin For Triggering Oocyte Maturation (clinicaltrials.gov) - P4 | N=134 | Not yet recruiting | Sponsor: Fundacion Dexeus

Head-to-Head • New P4 trial

Injection Free IVF (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Insel Gruppe AG, University Hospital Bern | N=112 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Gynecology

A study on the efficacy and safety of long-term adjusted low-dose gonadotropin-releasing hormone agonist therapy for uterine fibroids and adenomyosis. (PubMed, J Obstet Gynaecol Res) - "GnRH agonist drawback therapy was found to be useful for the long-term conservative treatment of uterine fibroids and adenomyosis. The treatment was safely and inexpensively performed with few adverse events."

Journal • Endometriosis • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation. (PubMed, ACS Appl Bio Mater) - "The model has been validated using in vitro release data obtained from implants of four drugs (buserelin, afamelanotide, brimonidine, and nafarelin). The model presented in this manuscript provides valuable insights into the kinetics and mechanism of drug release from PLGA-based solid implants and has demonstrated the potential for optimizing formulation design. The in vitro release model, coupled with physiologically based pharmacokinetic (PBPK) modeling, can predict the in vivo performance of implants and can be used to support bioequivalence studies in a drug development program."

Journal • Preclinical

Anti-Dengue: A Machine Learning-Assisted Prediction of Small Molecule Antivirals against Dengue Virus and Implications in Drug Repurposing. (PubMed, Viruses) - "We identified goserelin, gonadorelin, and nafarelin as potential repurposed drugs with high pIC50 values. "Anti-Dengue" may be beneficial in accelerating antiviral drug development against the dengue virus."

Journal • Machine learning • Dengue Fever

SOLOAGO: Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles (clinicaltrials.gov) - P3 | N=652 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Trial completion date: Jun 2027 ➔ Sep 2027 | Initiation date: Nov 2023 ➔ Feb 2024 | Trial primary completion date: Jun 2027 ➔ Sep 2027

Trial completion date • Trial initiation date • Trial primary completion date • Gynecology

SOLOAGO: Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles (clinicaltrials.gov) - P3 | N=652 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris

New P3 trial • Gynecology

Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors. (PubMed, Int J Mol Sci) - "A total of 23 approved drugs, including doramectin, glecaprevir, velpatasvir, ledipasvir, avermectin B1, nafarelin acetate, danoprevir, eltrombopag, lanatoside C, and glycyrrhizin, among others, were also predicted to have potential anti-EBOV activity and can be further explored so that they may be repurposed for EVD treatment. Molecular dynamics simulations coupled with molecular mechanics Poisson-Boltzmann surface area calculations corroborated the stability and good binding affinities of the complexes (-46.97 to -118.9 kJ/mol). The potential lead compounds may have the potential to be developed as anti-EBOV drugs after experimental testing."

Journal • Hematological Disorders • Infectious Disease

Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? (PubMed, Hum Reprod Open) - "Consuming less resources without negatively impacting on health outcomes carries ethical and practical implications for individuals and the community, as this approach may result in overall increased healthcare access."

HEOR • Journal • Review • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

"@Pfizer_UK any updates on Synarel shortages?" (@lottyloo72)

"@Pfizer_UK can you advice on shortages of Synarel? There are many patients in desperate need of it and pharmacies unable to source." (@lottyloo72)

Clinical

GnRH Agonist for Luteal Phase Support. (clinicaltrials.gov) - P=N/A | N=150 | Active, not recruiting | Sponsor: Shaare Zedek Medical Center

New trial

"داروی Nafarelineمتعاقب تجويز داخل بيني به سرعت جذب مي‌شود و اوج غلظت پلاسمايي آن طي 20 دقيقه حاصل مي‌شود اگر چه ميزان زيست دستيابي آن تنها حدود 3% است..از خراب نبودن دارو مطمئن شوید@merck" (@alidoki1)

Injection Free IVF (clinicaltrials.gov) - P2; N=112; Not yet recruiting; Sponsor: University Hospital Inselspital, Berne

New P2 trial • Gynecology

Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders (clinicaltrials.gov) - P4; N=100; Recruiting; Sponsor: Assaf-Harofeh Medical Center

Clinical • New P4 trial

"داروی Nafarelineمتعاقب تجويز داخل بيني به سرعت جذب مي‌شود و اوج غلظت پلاسمايي آن طي 20 دقيقه حاصل مي‌شود اگر چه ميزان زيست دستيابي آن تنها حدود 3% است.. @merck #dizziness افزایش قیمت دارو در بازار سیاه" (@KazemLali)